The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia

Exclusion criteria

• 1. Patients with a history of hypersensitivity to any cannabinoid or sesame oil. 2. Cannabinoid use in the previous 4 weeks (a urinary cannabinoid test will be performed before study entry). 3. Patients with a history of substance abuse, including alcohol abuse or dependence, or marijuana. 4. Seizure disorder with at least one epileptic seizure in the last 3 years or abnormal epileptic discharge in electroencephalography 5. Patients with history of bipolar disorder, severe depression or schizophrenia. 6. Patients that require driving, operating machinery, or engaging in hazardous activities. 7. Patients taking medications thought, in the investigator's opinion, to be unsafe when used with dronabinol. 8. Patients with atrial fibrillation, angina or an electrocardiogram documenting a significant abnormality that may jeopardize the patient's health. 9. Patients with significant pulmonary, liver, renal (creatinine \> 2.0 mg/ml), or cardiac illness that may, in the investigators opinion jeopardize their health by participating in this pilot trial. 10. Patients with severe cognitive impairment or pervasive developmental disorders, or patients who are unable to clearly identify and rate their symptoms of nausea. 11. Women who are pregnant or lactating. 12. Patients who have a significant abnormality on clinical examination that may, in the investigator's opinion, jeopardize their health by participating in this pilot trial.